NEW YORK (360Dx) – InBios announced today that it has received 510(k) clearance from the US Food and Drug Administration for an antibody-based point-of-care, rapid test that detects Chagas disease.

The firm's Chagas Detect Plus Rapid Test Kit, developed in collaboration with the Infectious Disease Research Institute in Seattle, employs an immunochromatographic strip assay to detect human IgG antibodies to Trypanosoma cruzi in human serum and whole blood matrices, including venous and capillary whole blood.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.